Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Cystitis | Research

Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome

Authors: Robert M. Moldwin, Vishaan Nursey, Oksana Yaskiv, Siddhartha Dalvi, Eric J. Macdonald, Michael Funaro, Chengliang Zhang, William DeGouveia, Marina Ruzimovsky, Horacio R. Rilo, Edmund J. Miller, Souhel Najjar, Inna Tabansky, Joel N. H. Stern

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disorder characterized by bladder pain upon filling which severely affects quality of life. Clinical presentation can vary. Local inflammatory events typify the clinical presentation of IC/BPS patients with Hunner lesions (IC/BPS-HL). It has previously been proposed that B cells are more prevalent in HL, but understanding their exact role in this environment requires a more complete immunological profile of HL. We characterized immunological dysfunction specifically in HL using immunohistochemistry. We detected significantly more plasma cells (50× increase, p < 0.0001), B cells (28× increase, p < 0.0001), T cells (3× increase, p < 0.0001), monocytes/macrophages (6× increase, p < 0.0001), granulocytes (4× increase, p < 0.0001), and natural killer cells (2× increase, p = 0.0249) in IC/BPS patients with HL than in unaffected controls (UC). Patients with IC/BPS-HL also had significantly elevated urinary levels of IL-6 (p = 0.0054), TNF-α (p = 0.0064) and IL-13 (p = 0.0304) compared to patients with IC/BPS without HL (IC/BPS-NHL). In contrast, IL-12p70 levels were significantly lower in the patients with HL than in those without these lesions (p = 0.0422). Different cytokines were elevated in the urine of IC/BPS patients with and without HL, indicating that different disease processes are active in IC/BPS patients with and without HL. Elevated levels of CD138+, CD20+, and CD3+ cells in HL are consistent B and T-cell involvement in disease processes within HL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Duh K, et al. Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome. Discov Med. 2018;25(139):243–50.PubMed Duh K, et al. Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome. Discov Med. 2018;25(139):243–50.PubMed
2.
go back to reference Keller JJ, Chen YK, Lin HC. Comorbidities of bladder pain syndrome/interstitial cystitis: a population-based study. BJU Int. 2012;110(11 Pt C):E903–9.CrossRef Keller JJ, Chen YK, Lin HC. Comorbidities of bladder pain syndrome/interstitial cystitis: a population-based study. BJU Int. 2012;110(11 Pt C):E903–9.CrossRef
3.
go back to reference Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.CrossRef Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.CrossRef
4.
go back to reference Whitmore KE, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26(Suppl 1):26–34.CrossRef Whitmore KE, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26(Suppl 1):26–34.CrossRef
5.
go back to reference van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007;4(9):484–91.CrossRef van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007;4(9):484–91.CrossRef
6.
go back to reference Peeker R, Atanasiu L, Logadottir Y. Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol. 2003;37(1):60–3.CrossRef Peeker R, Atanasiu L, Logadottir Y. Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol. 2003;37(1):60–3.CrossRef
7.
go back to reference Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990;143(6):1118–24.CrossRef Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990;143(6):1118–24.CrossRef
8.
go back to reference Shaik-Dasthagirisaheb YB, et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol. 2013;26(2):327–35.CrossRef Shaik-Dasthagirisaheb YB, et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol. 2013;26(2):327–35.CrossRef
9.
go back to reference Lotz M, et al. Interleukin-6 and interstitial cystitis. J Urol. 1994;152(3):869–73.CrossRef Lotz M, et al. Interleukin-6 and interstitial cystitis. J Urol. 1994;152(3):869–73.CrossRef
10.
go back to reference Saban R, et al. Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients. Am J Physiol Renal Physiol. 2008;295(6):F1613–23.CrossRef Saban R, et al. Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients. Am J Physiol Renal Physiol. 2008;295(6):F1613–23.CrossRef
11.
go back to reference Kochiashvili G, Kochiashvili D. Urinary IL-33 and galectin-3 increase in patients with interstitial cystitis/bladder pain syndrome (review). Georgian Med News. 2014;232–233:12–5. Kochiashvili G, Kochiashvili D. Urinary IL-33 and galectin-3 increase in patients with interstitial cystitis/bladder pain syndrome (review). Georgian Med News. 2014;232–233:12–5.
12.
go back to reference Akiyama Y, et al. Increased CXCR3 expression of infiltrating plasma cells in Hunner type interstitial cystitis. Sci Rep. 2016;6:28652.CrossRef Akiyama Y, et al. Increased CXCR3 expression of infiltrating plasma cells in Hunner type interstitial cystitis. Sci Rep. 2016;6:28652.CrossRef
13.
go back to reference Kuo HC. Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(Suppl 1):34–41.CrossRef Kuo HC. Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(Suppl 1):34–41.CrossRef
14.
go back to reference Gamper M, et al. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int Urogynecol J. 2013;24(12):2049–57.CrossRef Gamper M, et al. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int Urogynecol J. 2013;24(12):2049–57.CrossRef
15.
go back to reference Maeda D, et al. Hunner-type (classic) interstitial cystitis: a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation. PLoS ONE. 2015;10(11): e0143316.CrossRef Maeda D, et al. Hunner-type (classic) interstitial cystitis: a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation. PLoS ONE. 2015;10(11): e0143316.CrossRef
16.
go back to reference Price JW. Creatinine normalization of workplace urine drug tests: does it make a difference? J Addict Med. 2013;7(2):129–32.CrossRef Price JW. Creatinine normalization of workplace urine drug tests: does it make a difference? J Addict Med. 2013;7(2):129–32.CrossRef
17.
go back to reference Khamis MM, et al. Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD. Metabolomics. 2018;14(9):115.CrossRef Khamis MM, et al. Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD. Metabolomics. 2018;14(9):115.CrossRef
18.
go back to reference Cone EJ, et al. Normalization of urinary drug concentrations with specific gravity and creatinine. J Anal Toxicol. 2009;33(1):1–7.CrossRef Cone EJ, et al. Normalization of urinary drug concentrations with specific gravity and creatinine. J Anal Toxicol. 2009;33(1):1–7.CrossRef
19.
go back to reference Adedeji AO, et al. Investigating the value of urine volume, creatinine, and cystatin C for urinary biomarkers normalization for drug development studies. Int J Toxicol. 2019;38(1):12–22.CrossRef Adedeji AO, et al. Investigating the value of urine volume, creatinine, and cystatin C for urinary biomarkers normalization for drug development studies. Int J Toxicol. 2019;38(1):12–22.CrossRef
20.
go back to reference Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10): a016295.CrossRef Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10): a016295.CrossRef
21.
go back to reference Brinkman BM, et al. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1995;46(1):32–41.PubMed Brinkman BM, et al. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1995;46(1):32–41.PubMed
22.
go back to reference Agnello D, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23(3):147–61.CrossRef Agnello D, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23(3):147–61.CrossRef
23.
go back to reference Grandclaudon M, et al. A quantitative multivariate model of human dendritic cell-T helper cell communication. Cell. 2019;179(2):432-447.e21.CrossRef Grandclaudon M, et al. A quantitative multivariate model of human dendritic cell-T helper cell communication. Cell. 2019;179(2):432-447.e21.CrossRef
24.
go back to reference Lamale LM, et al. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006;68(4):702–6.CrossRef Lamale LM, et al. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006;68(4):702–6.CrossRef
25.
go back to reference Sundvall PD, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr. 2014;14:88.CrossRef Sundvall PD, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr. 2014;14:88.CrossRef
26.
go back to reference Jiang YH, et al. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS ONE. 2013;8(10): e76779.CrossRef Jiang YH, et al. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS ONE. 2013;8(10): e76779.CrossRef
27.
go back to reference Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012;79(2):484-e7.CrossRef Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012;79(2):484-e7.CrossRef
28.
go back to reference Schrepf A, et al. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: associations with painful symptoms. Pain. 2014;155(9):1755–61.CrossRef Schrepf A, et al. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: associations with painful symptoms. Pain. 2014;155(9):1755–61.CrossRef
29.
go back to reference Schweighoffer E, et al. TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK. J Exp Med. 2017;214(5):1269–80.CrossRef Schweighoffer E, et al. TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK. J Exp Med. 2017;214(5):1269–80.CrossRef
Metadata
Title
Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome
Authors
Robert M. Moldwin
Vishaan Nursey
Oksana Yaskiv
Siddhartha Dalvi
Eric J. Macdonald
Michael Funaro
Chengliang Zhang
William DeGouveia
Marina Ruzimovsky
Horacio R. Rilo
Edmund J. Miller
Souhel Najjar
Inna Tabansky
Joel N. H. Stern
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03236-7

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine